חוב לטווח קצר להון Immuron (IMRN)

Immuron Limited (IMRN) operations are constrained by risks of Asian supply chain disruptions and patent conflicts, which is confirmed by the price trend reflected below, where the indicator is 0.00. The company develops innovative colostrum-based products to combat intestinal infections. Growth in the customer base is driven by US Army government contracts and the FDA dietary supplement status for Travelan.

This indicator compares the volume of liabilities maturing within one year against the amount of equity, measuring liquidity risk and dependence on external borrowing. By analyzing the short-term debt-to-equity ratio, an investor assesses the financial stability of Immuron Limited (IMRN), where a low debt load is critical for the uninterrupted conduct of clinical trials and the commercialization of medical developments regardless of market conditions.